Nektar Therapeutics
NKTR58.760USD
+7.690+15.06%
Cierre 09/18, 16:00（ET）Cotizaciones retrasadas 15 min
731.99MCap. mercado
PérdidaP/E TTM
Más Datos de Nektar Therapeutics Compañía
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Información de la empresa
Símbolo de cotizaciónNKTR
Nombre de la empresaNektar Therapeutics
Fecha de salida a bolsaMay 03, 1994
Director ejecutivoMr. Howard W. Robin
Número de empleados61
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 03
Dirección455 Mission Bay Boulevard South
CiudadSAN FRANCISCO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94158
Teléfono18554826587
Sitio Webhttps://www.nektar.com/
Símbolo de cotizaciónNKTR
Fecha de salida a bolsaMay 03, 1994
Director ejecutivoMr. Howard W. Robin
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.83K
-32.35%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
15.15K
-12.71%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Sandra A. Gardiner
Ms. Sandra A. Gardiner
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Mark A. Wilson, J.D.
Mr. Mark A. Wilson, J.D.
Senior Vice President, Chief Legal Officer
Senior Vice President, Chief Legal Officer
--
--
Mr. Corey Davis
Mr. Corey Davis
Managing Director
Managing Director
--
--
Mr. Roy A. Whitfield
Mr. Roy A. Whitfield
Lead Independent Director
Lead Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.83K
-32.35%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
15.15K
-12.71%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
Rest of world
97.05M
98.60%
United States
1.38M
1.40%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 10 de sep
Actualizado: mié., 10 de sep
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BVF Partners L.P.
6.71%
The Vanguard Group, Inc.
3.84%
Nantahala Capital Management, LLC
3.73%
Millennium Management LLC
3.41%
AQR Capital Management, LLC
2.25%
Otro
80.06%
Accionistas
Accionistas
Proporción
BVF Partners L.P.
6.71%
The Vanguard Group, Inc.
3.84%
Nantahala Capital Management, LLC
3.73%
Millennium Management LLC
3.41%
AQR Capital Management, LLC
2.25%
Otro
80.06%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
22.42%
Investment Advisor
14.24%
Investment Advisor/Hedge Fund
9.72%
Research Firm
1.82%
Individual Investor
0.71%
Family Office
0.23%
Venture Capital
0.08%
Pension Fund
0.01%
Otro
50.76%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
342
8.92M
53.56%
-2.95M
2025Q1
408
8.48M
68.15%
-4.47M
2024Q4
427
136.20M
73.84%
-69.28M
2024Q3
442
143.71M
78.07%
-57.20M
2024Q2
458
138.43M
75.38%
-54.08M
2024Q1
477
115.32M
62.79%
-91.21M
2023Q4
499
122.94M
64.45%
-94.24M
2023Q3
522
148.15M
77.94%
-68.45M
2023Q2
531
142.56M
75.34%
-88.27M
2023Q1
545
178.73M
94.47%
-35.40M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
820.65K
4.92%
-1.22K
-0.15%
Mar 31, 2025
Nantahala Capital Management, LLC
519.27K
3.12%
-1.40K
-0.27%
Mar 31, 2025
Millennium Management LLC
932.86K
5.6%
+780.28K
+511.36%
Jun 27, 2025
AQR Capital Management, LLC
242.72K
1.46%
+187.17K
+336.95%
Mar 31, 2025
Acadian Asset Management LLC
486.78K
2.92%
+6.71K
+1.40%
Mar 31, 2025
PRIMECAP Management Company
356.97K
2.14%
-12.39K
-3.35%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
873.88K
5.24%
-15.04K
-1.69%
Mar 31, 2025
TCG Crossover Management, LLC
266.67K
1.6%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: mar., 2 de sep
Actualizado: mar., 2 de sep
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.9%
Simplify Health Care ETF
0.84%
Fidelity Enhanced Small Cap ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
Schwab U.S. Small-Cap ETF
0.01%
iShares Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Value ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.9%
Simplify Health Care ETF
Proporción0.84%
Fidelity Enhanced Small Cap ETF
Proporción0.04%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.03%
Schwab U.S. Small-Cap ETF
Proporción0.01%
iShares Biotechnology ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
iShares Russell 2000 Value ETF
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
ProShares Ultra Nasdaq Biotechnology
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
